IVERIC BIO INC: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei IVERIC BIO INC listata cu simbolul US.ISEE ==Descriere companie== IVERIC bio, Inc. (https://ivericbio.com/) is a biopharmaceutical company. The Company is engaged in the discovery and development of treatment options for retinal diseases. The Company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). The Company's therapeutics portfolio...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 1: | Linia 1: | ||
Pagina dedicata companiei IVERIC BIO INC listata cu simbolul US.ISEE | Pagina dedicata companiei IVERIC [[BIO]] INC listata cu simbolul US.ISEE | ||
==Descriere companie== | ==Descriere companie== | ||
Versiunea curentă din 26 noiembrie 2024 16:07
Pagina dedicata companiei IVERIC BIO INC listata cu simbolul US.ISEE
Descriere companie[edit | ]
IVERIC bio, Inc. (https://ivericbio.com/) is a biopharmaceutical company. The Company is engaged in the discovery and development of treatment options for retinal diseases. The Company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). The Company's therapeutics portfolio consists of Zimura (avacincaptad pegol), a complement C5 inhibitor, and IC-500, a high-temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor. The Company's gene therapy portfolio consists of two product candidates in pre-clinical development, IC-100 and IC-200. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.
Grafic actiuni companie[edit | ]